home / stock / athjf / athjf quote
Last: | $0.01 |
---|---|
Change Percent: | 0.0% |
Open: | $0.01 |
Close: | $0.01 |
High: | $0.01 |
Low: | $0.01 |
Volume: | 24,000 |
Last Trade Date Time: | 12/28/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 24,000 | 12-28-2023 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 10,000 | 11-02-2023 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 2,500 | 10-10-2023 |
$0.05 | $0 | $0.05 | $0 | $0 | 195 | 09-27-2023 |
$0.05 | $0 | $0.05 | $0 | $0 | 241,215 | 09-22-2023 |
$0.05 | $0 | $0.05 | $0 | $0 | 89,881 | 09-21-2023 |
$0.05 | $0 | $0.05 | $0 | $0 | 68,904 | 09-20-2023 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 10,000 | 07-05-2023 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 10,000 | 06-08-2023 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 10,000 | 05-23-2023 |
$0.041835 | $0.05 | $0.041835 | $0.05 | $0.041835 | 11,000 | 05-22-2023 |
$0.05 | $0.05 | $0.05 | $0.05 | $0.05 | 30,000 | 05-18-2023 |
$0.055 | $0.055 | $0.055 | $0.055 | $0.055 | 586 | 05-01-2023 |
$0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 74,100 | 04-07-2023 |
$0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 74,100 | 04-06-2023 |
$0.057935 | $0.057935 | $0.057935 | $0.057935 | $0.057935 | 1,000 | 02-10-2023 |
$0.06806 | $0.06806 | $0.06806 | $0.06806 | $0.06806 | 5,000 | 01-30-2023 |
$0.0501 | $0.05 | $0.0501 | $0.0501 | $0.05 | 10,000 | 01-26-2023 |
$0.088 | $0.088 | $0.088 | $0.088 | $0.088 | 4,800 | 01-18-2023 |
$0.065 | $0.065 | $0.065 | $0.065 | $0.065 | 900 | 12-01-2022 |
News, Short Squeeze, Breakout and More Instantly...
Antisense Therapeutics Company Name:
ATHJF Stock Symbol:
OTCMKTS Market:
Antisense Therapeutics Website:
New York, NY, March 09, 2022 (GLOBE NEWSWIRE) -- Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] will deliver a virtual presentation on its antisense drug at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference later this week. Dr. George ...
MELBOURNE, AUSTRALIA / ACCESSWIRE / May 23, 2018 / Antisense Therapeutics (the "Company" or "ANP") (ASX: ANP; OTC PINK: ATHJF) is pleased to announce the acceptance for publication of previously reported positive Phase II clinical trial data on ATL1103 (atesidorsen) in the leading peer-revie...
MELBOURNE, AUSTRALIA / ACCESSWIRE / February 28, 2018 / Antisense Therapeutics ("ANP" or the "Company") (ASX: ANP; OTC PINK: ATHJF) is pleased to advise that the Company has received approval from the Royal Children's Hospital (RCH), Melbourne Human Research Ethics Committee, to undertake a ...